What is the interpretation and clinical significance of a coronary artery calcium (CAC) score?

Coronary Artery Calcium Score Interpretation and Clinical Significance

The coronary artery calcium (CAC) score is the single most powerful tool for cardiovascular risk stratification in asymptomatic individuals, directly quantifying atherosclerotic burden and guiding statin therapy decisions with clear treatment thresholds: CAC = 0 allows safe deferral of statins, CAC 1-99 favors statins in those >55 years, and CAC ≥100 mandates statin initiation. 1

What the CAC Score Measures

The CAC score quantifies calcified atherosclerotic plaque in coronary arteries using non-contrast ECG-gated CT scanning. Critically, CAC represents only 20% of total atherosclerotic burden since not all plaques are calcified, making it a marker of atherosclerosis presence rather than stenosis severity. 2 The Agatston score is the universal standard, calculated by multiplying lesion area by a density-weighted factor (1-4 based on CT density >130 Hounsfield units). 2

Risk Stratification Categories

The score stratifies patients into clear prognostic groups 2:

• CAC = 0: Very low risk (<1% annual cardiac death/MI), excellent 10-year prognosis
• CAC 1-100: Low risk (<10% 10-year events)
• CAC 101-400: Intermediate risk (10-20% 10-year events)
• CAC >400: High risk (>20% 10-year events)
• CAC >1000: Very high risk (33% will have cardiovascular event within 3 years) 3

The percentile ranking (adjusted for age, sex, and race) matters as much as the absolute score—being above the 75th percentile upgrades risk even with moderate absolute scores. 1

The "Power of Zero"

A CAC score of 0 provides a "warranty period" of extremely low risk, with only 0.47% experiencing adverse cardiovascular events over 50 months of follow-up. 2 This holds true even in:

• Patients classified as high-risk by traditional calculators (Framingham >20%)
• Diabetic patients (though only for the first 5 years) 2
• Those with multiple risk factors

The warranty period varies: younger patients and those without diabetes can safely defer rescanning for 5-7 years, while diabetics and older patients should reconsider in 3-5 years. 2

Who Should Get CAC Scoring

All major guidelines agree on these indications 1:

Primary candidates:

• Age ≥40 years
• Asymptomatic
• Intermediate 10-year ASCVD risk (7.5-20%) where treatment decision is uncertain
• Borderline risk (5-7.5%) with risk-enhancing factors (family history of premature CAD, metabolic syndrome, chronic inflammatory conditions)

Special populations to consider:

• Type 1 diabetes <35 years or Type 2 diabetes <50 years with disease duration <10 years
• Low-risk patients with strong family history of premature CVD
• High-risk patients reluctant to accept statin therapy (to motivate treatment)

Do NOT use CAC scoring in:

• Known CAD patients (already high-risk)
• Symptomatic patients (CAC = 0 does NOT exclude obstructive disease—7-38% of symptomatic patients with CAC = 0 have significant stenosis) 2
• Already committed to statin therapy regardless of result

Treatment Thresholds: The Critical Decision Points

CAC = 0: 1, 2

• Downgrade risk classification
• Withhold statin therapy (unless active smoking, diabetes, or strong family history of premature CAD)
• Emphasize lifestyle modification
• Rescan in 3-7 years depending on risk factors

CAC 1-99: 1, 2

• Favor moderate-intensity statin, especially if age >55 years
• 10-year ASCVD risk typically 7.4% in borderline-risk patients
• Lifestyle modification remains critical

CAC ≥100: 1, 2

• Initiate or consider high-intensity statin therapy
• Some guidelines recommend aspirin 81 mg daily (though this remains controversial between guidelines)
• Number needed to treat (NNT) = 30 to prevent one ASCVD event over 5 years (even without lipid abnormalities) 2
• Aggressive risk factor modification mandatory

CAC >400: 2

• Consider screening for silent ischemia per ACC/AHA 2010 guidelines
• Very high-intensity preventive therapy

CAC >1000: 3

• Extremely high risk requiring maximal medical therapy
• One-third will have cardiovascular event within 3 years

Location Matters: Left Main and Multi-Vessel Disease

The presence of left main coronary artery (LMCA) calcification dramatically worsens prognosis independent of total score. 2 Annual mortality reaches 7.71% when LMCA CAC >400. Mortality risk increases 20% if <25% of total CAC is in the LMCA and 40% if >25% is in the LMCA. 2

Multi-vessel involvement (2-vessel, 3-vessel, or 3-vessel + LMCA) independently predicts higher mortality beyond the total Agatston score. 2 Always report the number of vessels involved and specifically highlight LMCA calcification.

Common Pitfalls to Avoid

1. Do not use CAC to exclude disease in symptomatic patients—up to 38% with chest pain and CAC = 0 have obstructive disease 2

2. Do not ignore the percentile ranking—a 50-year-old with CAC = 50 may be at the 90th percentile (high risk), while a 70-year-old with the same score may be at the 50th percentile (average risk)

3. Do not assume CAC = 0 provides lifetime protection—the warranty expires faster in diabetics (5 years) and those with multiple risk factors 2

4. Do not routinely rescan patients with positive scores—no current guideline supports this, though annual increases >15% or >100 units predict worse outcomes 4

5. Statin therapy interpretation requires caution—statins may increase CAC density (stabilizing plaques) while reducing cardiovascular events, so serial CAC changes on statins don't reflect treatment failure 2

Clinical Impact Beyond Risk Stratification

CAC scoring motivates patient behavior change. Patients with CAC >0 demonstrate better blood pressure control, improved lipid levels, and higher rates of starting and continuing preventive therapies compared to those without visible atherosclerosis. 2 This "teachable moment" effect enhances the value beyond pure risk calculation.

Cost-Effectiveness

CAC scoring is most cost-effective in intermediate-risk patients when treatment is actually applied based on results. 2 The NNT to prevent one ASCVD event over 10 years is 64 for CAC = 0 (suggesting statins can be safely withheld) versus 28 for CAC >100 (justifying treatment). 2 The radiation exposure is minimal (0.37 mSv), less than screening mammography. 2

Practical Algorithm for Clinical Use

1. Calculate 10-year ASCVD risk using pooled cohort equation or MESA calculator
2. If intermediate risk (7.5-20%) or borderline risk (5-7.5%) with uncertainty about statin therapy → Order CAC scoring
3. Interpret result:
   • CAC = 0: Defer statin, lifestyle modification, rescan 3-7 years
   • CAC 1-99 and age >55: Start moderate-intensity statin
   • CAC ≥100: Start high-intensity statin, consider aspirin
   • CAC >400: Maximal medical therapy, consider stress testing
4. Report percentile, vessel involvement, and LMCA involvement to guide intensity of therapy
5. Use result to engage patient in shared decision-making and motivate adherence

The CAC score transforms abstract cardiovascular risk into visible, quantifiable disease burden, making it the most powerful tool for personalizing primary prevention strategies in asymptomatic individuals. 2